Alliance Global Partners raised the price target for the Rigetti Computing Inc (NASDAQ:RGTI) stock to “a Buy”. The rating was released on March 01, 2024, according to finviz. The stock was downgraded ...

Currently, 5.07 percent of Chegg Inc shares are owned by insiders, and 92.71 percent are held by financial institutions. Schultz Nathan J., the CHIEF OPERATING OFFICER at Chegg Inc (CHGG) has sold ...

H.C. Wainwright raised the price target for the Aclaris Therapeutics Inc (NASDAQ:ACRS) stock from “a Buy” to “a Neutral”. The rating was released on January 22, 2024, according to finviz. The research ...

Morgan Stanley lowered the price target for the FREYR Battery Inc. (NYSE:FREY) stock from “an Overweight” to “an Equal-weight”. The rating was released on November 14, 2023, according to finviz. The ...

Currently, 19.92 percent of ParaZero Technologies Ltd shares are owned by insiders, and 1.17 percent are held by financial institutions.

Wells Fargo lowered the price target for the E.W. Scripps Co. (NASDAQ:SSP) stock from “an Overweight” to “an Equal weight”. The rating was released on November 09, 2022, according to finviz. The ...

Jefferies raised the price target for the Verona Pharma Plc ADR (NASDAQ:VRNA) stock to “a Buy”. The rating was released on May 22, 2023, according to finviz. The research report from Piper Sandler has ...

BofA Securities lowered the price target for the Luminar Technologies Inc (NASDAQ:LAZR) stock from “a Neutral” to “an Underperform”. The rating was released on April 10, 2024, according to finviz. We ...

Mizuho lowered the price target for the Revance Therapeutics Inc (NASDAQ:RVNC) stock from “a Buy” to “a Neutral”. The rating was released on January 29, 2024, according to finviz. We previously noted ...

Deutsche Bank raised the price target for the Arqit Quantum Inc (NASDAQ:ARQQ) stock to “a Hold”. The rating was released on July 19, 2022, according to finviz.

Piper Sandler raised the price target for the Black Diamond Therapeutics Inc (NASDAQ:BDTX) stock to “an Overweight”. The rating was released on July 14, 2023, according to finviz. We previously noted ...

Maxim Group raised the price target for the Citius Pharmaceuticals Inc (NASDAQ:CTXR) stock to “a Buy”. The rating was released on November 30, 2021, according to finviz.